Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer.


Journal

European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796

Informations de publication

Date de publication:
01 10 2020
Historique:
received: 11 09 2019
accepted: 10 03 2020
pubmed: 14 3 2020
medline: 6 7 2021
entrez: 14 3 2020
Statut: ppublish

Résumé

The prognostic importance of post-diagnosis assessment of cardiorespiratory fitness (CRF) in cancer patients is not well established. We sought to examine the association between CRF and mortality in cancer patients. This was a single-centre cohort analysis of 1632 patients (58% male; 64 ± 12 years) with adult-onset cancer who were clinically referred for exercise treadmill testing a median of 7 [interquartile range (IQR): 3-12] years after primary diagnosis. Cardiorespiratory fitness was defined as peak metabolic equivalents (METs) achieved during standard Bruce protocol and categorized by tertiles. The association between CRF and all-cause and cause-specific mortality was assessed using multivariable Cox proportional hazard models adjusting for important covariates. Median follow-up was 4.6 (IQR: 2.6-7.0) years; a total of 411 deaths (229, 50, and 132 all-cause, cardiovascular (CV), and cancer related, respectively) occurred during this period. Compared with low CRF (range: 1.9-7.6 METs), the adjusted hazard ratio (HR) for all-cause mortality was 0.38 [95% confidence interval (CI): 0.28-0.52] for intermediate CRF (range: 7.7-10.6 METs) and 0.17 (95% CI: 0.11-0.27) for high CRF (range: 10.7-22.0 METs). The corresponding HRs were 0.40 (95% CI: 0.19-0.86) and 0.41 (95% CI: 0.16-1.05) for CV mortality and 0.40 (95% CI: 0.26-0.60) and 0.16 (95% CI: 0.09-0.28) for cancer mortality, respectively. The adjusted risk of all-cause, CV, and cancer mortality decreased by 26%, 14%, and 25%, respectively with each one MET increment in CRF. Cardiorespiratory fitness is a strong, independent predictor of all-cause, CV, and cancer mortality, even after adjustment for important clinical covariates in patients with certain cancers.

Identifiants

pubmed: 32167560
pii: 5804986
doi: 10.1093/ehjqcco/qcaa015
pmc: PMC9989596
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

315-322

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Références

Lung Cancer. 2012 May;76(2):248-52
pubmed: 22112290
Bone Marrow Transplant. 2014 Oct;49(10):1330-6
pubmed: 25068429
J Am Coll Cardiol. 2003 Dec 17;42(12):2139-43
pubmed: 14680741
J Am Soc Echocardiogr. 2013 Sep;26(9):1013-32
pubmed: 23998694
J Clin Oncol. 2003 May 1;21(9):1819-24
pubmed: 12721259
J Heart Lung Transplant. 1995 Sep-Oct;14(5):981-9
pubmed: 8800737
JAMA Oncol. 2015 May;1(2):231-7
pubmed: 26181028
Bone Marrow Transplant. 2013 Oct;48(10):1342-9
pubmed: 23584437
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Cancer Med. 2019 Jan;8(1):447-454
pubmed: 30578624
Cancer. 2005 Nov 1;104(9):1998-2005
pubmed: 16206252
J Clin Oncol. 2017 Mar 10;35(8):893-911
pubmed: 27918725
N Engl J Med. 2002 Mar 14;346(11):793-801
pubmed: 11893790
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
JAMA Netw Open. 2018 Oct 5;1(6):e183605
pubmed: 30646252
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Acta Oncol. 2016 Dec;55(12):1386-1391
pubmed: 27718777
Circulation. 2017 Apr 18;135(16):e894-e918
pubmed: 28336790
J Am Coll Cardiol. 2015 Feb 17;65(6):573-83
pubmed: 25677317
JAMA Oncol. 2018 Oct 1;4(10):1352-1358
pubmed: 29862412
J Clin Oncol. 2012 Jul 10;30(20):2530-7
pubmed: 22614980
J Clin Oncol. 1995 Jun;13(6):1453-8
pubmed: 7751892
Lancet Oncol. 2009 Jun;10(6):598-605
pubmed: 19482248
Circulation. 2002 Aug 6;106(6):666-71
pubmed: 12163425
Circ J. 2008 Apr;72(4):575-81
pubmed: 18362428
Am Heart J. 1999 Oct;138(4 Pt 1):740-5
pubmed: 10502221
Chest. 2007 Dec;132(6):1778-85
pubmed: 17925409
Circulation. 2013 Aug 20;128(8):873-934
pubmed: 23877260
Br J Cancer. 1997;75(5):698-702
pubmed: 9043027
Circulation. 2003 Sep 30;108(13):1554-9
pubmed: 12975254
Ann Palliat Med. 2016 Apr;5(2):83-92
pubmed: 27121736
Circulation. 1998 Dec 22-29;98(25):2836-41
pubmed: 9860784
J Clin Oncol. 1996 Aug;14(8):2197-205
pubmed: 8708708
Br J Cancer. 2016 Jul 12;115(2):178-87
pubmed: 27351215
J Clin Oncol. 2018 Aug 1;36(22):2297-2305
pubmed: 29894274
Cancer. 2010 Oct 15;116(20):4825-32
pubmed: 20597134
Clin Cancer Res. 2016 Oct 1;22(19):4766-4775
pubmed: 27407093
Circulation. 1997 Jul 1;96(1):345-54
pubmed: 9236456
Circulation. 2019 May 21;139(21):e997-e1012
pubmed: 30955352
J Clin Oncol. 2000 Feb;18(3):562-73
pubmed: 10653871
Ann Oncol. 2001 Jan;12(1):81-7
pubmed: 11249054
Angiology. 1973 Dec;24(11):691-702
pubmed: 4543577

Auteurs

John D Groarke (JD)

Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Adult Survivorship Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, 450 Brookline Avenue, Boston, MA 02215, USA.

David L Payne (DL)

Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

Brian Claggett (B)

Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

Mandeep R Mehra (MR)

Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

Jingyi Gong (J)

Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

Jesse Caron (J)

Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

Syed S Mahmood (SS)

Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

Jon Hainer (J)

Noninvasive Cardiovascular Imaging Program, Department of Radiology, Brigham and Women's Hospital, Boston, MA 02115, USA.

Tomas G Neilan (TG)

Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114-2696, USA.

Ann H Partridge (AH)

Adult Survivorship Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, 450 Brookline Avenue, Boston, MA 02215, USA.

Marcelo Di Carli (M)

Noninvasive Cardiovascular Imaging Program, Department of Radiology, Brigham and Women's Hospital, Boston, MA 02115, USA.

Lee W Jones (LW)

Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

Anju Nohria (A)

Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Adult Survivorship Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, 450 Brookline Avenue, Boston, MA 02215, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH